18665797. Novel Pyridine Compounds simplified abstract (Hoffmann-La Roche Inc.)

Novel Pyridine Compounds

Organization Name

Hoffmann-La Roche Inc.

Inventor(s)

Mark Chapman of Durham NC (US)

Nicholas Gareth Morse Davies of Durham NC (US)

Aaron Gerlach of Durham NC (US)

Sylvain Lebreton of Tucson AZ (US)

Ingrid Mechin of Durham NC (US)

David Mowrey of Durham NC (US)

Karthigeyan Nagarajan of Durham NC (US)

Anil Nair of Durham NC (US)

Roger David Norcross of Aargau (CH)

Roger Lluis Redondo Pena of Basel (CH)

Alena Safarova of Durham NC (US)

Martin Smrcina of Durham NC (US)

Novel Pyridine Compounds - A simplified explanation of the abstract

This abstract first appeared for US patent application 18665797 titled 'Novel Pyridine Compounds

The invention provides new heterocyclic compounds having the general formula (I), or a solvate or a pharmaceutically acceptable salt thereof.

• These new heterocyclic compounds have the potential for various applications in the pharmaceutical industry.
• The compounds can be used in the development of novel drugs targeting specific diseases or conditions.
• They offer a unique chemical structure that may lead to improved efficacy and reduced side effects in drug formulations.
• The invention addresses the need for innovative compounds with diverse pharmacological properties.
• The compounds may have commercial applications in drug discovery and development, potentially impacting the market with new treatment options.

Potential Applications: These compounds could be utilized in the development of new pharmaceuticals for various medical conditions. They may serve as lead compounds for drug discovery programs targeting specific biological pathways. The compounds could be used in preclinical and clinical studies to evaluate their therapeutic potential.

Problems Solved: The invention provides a solution to the demand for novel heterocyclic compounds with potential pharmacological benefits. It addresses the need for innovative drug candidates with unique chemical structures for improved therapeutic outcomes.

Benefits: The compounds offer the potential for developing new and more effective drugs. They may lead to advancements in the treatment of various diseases and medical conditions. The invention opens up possibilities for creating safer and more targeted pharmaceutical interventions.

Commercial Applications: The new heterocyclic compounds could have significant commercial value in the pharmaceutical industry. They may attract interest from drug development companies looking to expand their product pipelines. The compounds could potentially lead to the creation of marketable pharmaceutical products with improved therapeutic profiles.

Questions about the new heterocyclic compounds: 1. How do these compounds differ from existing heterocyclic structures in terms of pharmacological potential? These compounds offer unique chemical properties that may result in improved drug efficacy and reduced side effects compared to existing structures.

2. What specific medical conditions or diseases could these compounds potentially target? These compounds have the potential to be developed into drugs for a wide range of conditions, depending on their specific pharmacological properties and mechanisms of action.

Original Abstract Submitted

The invention provides new heterocyclic compounds having the general formula (I), or a solvate or a pharmaceutically acceptable salt thereof: